Tech Company Inital Public Offerings
Entasis Therapeutics IPO
Entasis Therapeutics was acquired by . Shares were listed on 9/25/2018.
Transaction Overview
Company Name
Announced On
9/25/2018
Transaction Type
IPO
Amount
$75,000,000
Proceeds Purpose
Proceeds will be used:to fund the advancement of ETX2514SUL through a Phase 3 clinical trial; to fund the advancement of ETX0282CPDP through a multi-part Phase 1 clinical trial; to fund the selection of an initial clinical candidate from our NBP development program and advance it through a Phase 1 clinical trial; and the remainder to fund other research and development activities, working capital and general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Entasis Therapeutics (Nasdaq: ETTX) is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Manos Perros
Chief Medical Officer
David Altarac
Chief Scientific Officer
Ruben Tommasi
VP - Bus. Development
Michael Gutch
VP - Bus. Development
Eric Kimble
VP - Bus. Development
John Mueller
Browse more venture capital transactions:
Prev: 9/25/2018: Renovia venture capital transaction
Next: 9/26/2018: MAXEX venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs